In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.
Modifiable risk factors accounted for only a fraction of the difference in stone rates between the sexes, according to investigators.
Among patients with nephrolithiasis or urolithiasis, the cardiovascular event rate was 74.4 per 1000 person-years.
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
An investigational targeted radiotherapy added to standard of care improved survival in men with previously treated mCRPC.
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
The frequency of targetable alterations was roughly 22% in patients of African ancestry and those of European ancestry.
TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT.
Pembrolizumab plus axitinib improved progression-free and overall survival.